ARTICLE | Clinical News

CTA018: Phase Ib data

August 8, 2005 7:00 AM UTC

In a 4-arm, open-label, Canadian Phase Ib trial in 28 patients with plaque psoriasis, CTA018 was safe at all tested doses. Patients applied 1, 3 or 10 ug/g topical CTA018 or a vehicle cream base to pl...